Cartesian Therapeutics, Inc. (RNAC)
(Delayed Data from NSDQ)
$13.75 USD
+0.38 (2.84%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $13.83 +0.08 (0.58%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
RNAC 13.75 +0.38(2.84%)
Will RNAC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RNAC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RNAC
Cartesian Therapeutics, Inc. (RNAC) Q2 Earnings and Revenues Top Estimates
Amicus Therapeutics (FOLD) Q2 Earnings and Revenues Top Estimates
RNAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
Other News for RNAC
Buy Recommendation for Cartesian Therapeutics on Robust Clinical Trials and Favorable Regulatory Prospects
Buy Rating Affirmed for Cartesian Therapeutics Amid Promising Clinical Trials and Regulatory Prospects
Oppenheimer Sticks to Their Hold Rating for Cartesian Therapeutics (RNAC)
Buy Rating Affirmed for Cartesian Therapeutics Amid Clinical Success and Strengthened Financials
Cartesian Therapeutics price target lowered by $4 at H.C. Wainwright, here's why